54 Completely Individualized Treatment Durations (24, 30, 36, 42, 48, 60 or 72 Weeks) With Peginterferon-Alfa-2b and Ribavirin in HCV Genotype 1-Infected Patients (Indiv-2 Study)

Sarrazin, C.; Schwendy, Susanne; Möller, B.; Dikopoulos, Nektarios; Buggisch, Peter; Encke, Jens; Teuber, G.; Goeser, Tobias; Thimme, Robert; Klinker, Hartwig; Boecher, WO; Schulte‐Frohlinde, E.; Prinzing, R.; Berg, T; Zeuzem, Stefan

doi:10.1016/s0168-8278(10)60056-6

Cited by 7 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, there are several published papers regarding the relationship between the IL28B genotype and SVR (also RVR or EVR) in Caucasian patients infected with HCV genotype 1. In the German study previously mentioned, the overall SVR after 48 weeks, with standard duration of treatment, was 48% (17). In our study in the western part of Romania, with the same standard 48-week treatment duration, the SVR was 50.5 %, similar to the German study.…”

Section: Discussionsupporting

confidence: 89%

“…In the same study, important differences were observed regarding several other parameters: the rapid virologic response (RVR; 28%, 5%, and 5% in patients with the C/C, C/T, and T/T genotypes, respectively); EVR (97%, 72%, and 68% in patients with the C/C, C/T, and T/T genotypes, respectively); the end-of-treatment response (EOT; 92%, 56%, and 51% in patients with the C/C, C/T, and T/T genotypes, respectively); relapse rates (14%, 27%, and 31% in patients with the C/C, C/T, and T/T genotypes, respectively). Another group tested if the IL28B genotype could be used to tailor treatment duration according to baseline viral load and virologic response during treatment in genotype 1 HCV patients (17). In this multicenter German study, 398 treatment-naive HCV genotype-1 patients were enrolled and treated with PegIFN and ribavirin.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C

Sporea¹,

Popescu²,

Curescu³

et al. 2012

Hepat Mon

View full text Add to dashboard Cite

Background: Multiple variables influencing the sustained virologic response (SVR) in chronic hepatitis C have been evaluated. One of them is genetic polymorphism near the IL28B gene. Objectives: The aim of this study was to evaluate the influence of IL28B genotypes on SVR rates in a group of patients with chronic hepatitis C from the western part of Romania. Patients and Methods: A retrospective study was performed in 107 consecutive patients, previously treated with standard-of-care medication for chronic hepatitis C, identified from the databases of 2 centers. Patient demographics, viral load before treatment and at 12, 24, and 72 weeks from the treatment start, and IL28B genotype were evaluated. Results: Among the 107 patents in the study group, 54 patients had SVR (50.5%), and 62 (57.9%) showed a complete early virologic response (cEVR). The SVR rates according to IL28B genotype were as follows: 73.1% in patients with genotype C/C, 40.9% in those with genotype C/T, and 57.1% in those with genotype T/T (i.e., 73.1% among patients with the C/C genotype vs. 43.7% among those with non-C/C genotypes; P = 0.0126). The cEVR rates were 80.8% in patients with the C/C genotype vs. 51.2% in those with non-C/C genotypes (P = 0.011). Conclusions: In our cohort of 107 Caucasian HCV patients, the SVR rate was 50.5% with standard-of-care treatment. The SVR rate was directly related to the IL28B genotype: 73.1% in the C/C genotype vs. 43.7% in non-C/C genotypes (P = 0.0126).

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C

Sporea¹,

Popescu²,

Curescu³

et al. 2012

Hepat Mon

View full text Add to dashboard Cite

show abstract

“…In addition, IL28B SNPs are strongly associated with SVR in patients who do not achieve RVR [43]. Sarrazin et al retrospectively evaluated the importance of IL28B SNPs in completely individualized treatment durations (24-72 weeks) with pegIFN-a and ribavirin in HCV genotype 1 patients [75]. Duration of treatment was defined by a responseguided approach according to the first time when HCV RNA fell below the limit of detection.…”

Section: Il28b Snps and Treatment With Directly Acting Antiviral Agentsmentioning

confidence: 99%

IL28B single nucleotide polymorphisms in the treatment of hepatitis C

Lange

Zeuzem

2011

Journal of Hepatology

View full text Add to dashboard Cite

Recent genome-wide association studies (GWAS) have identified genetic variations near the IL28B gene which are strongly associated with spontaneous and treatment-induced clearance of hepatitis C virus (HCV) infection. Protective IL28B variations are strongly associated with on-treatment viral kinetics and approximately 2-fold increased sustained virologic response (SVR) rates in HCV genotype 1 and 4 patients. In HCV genotype 1 patients, IL28B variations were shown to be the strongest pre-treatment predictor of virologic response. In the treatment of HCV genotype 2 and 3 infected patients, IL28B variations play only a minor role. Preliminary data indicate that IL28B variations are also associated with treatment outcome of regimens, including directly acting antiviral (DAA) agents, though their impact seems to be attenuated compared to standard treatment. Here, we review these important findings and discuss possible implications for clinical decision making in the treatment of HCV infection.

show abstract

“…Recent data from the INDIV‐2 study, where treatment was individualized according to the time to first undetectable HCV RNA, also confirm a favourable comparison of 24 weeks with 48 weeks of therapy in patients with G1 infection with baseline viral load <800 000 IU/mL who attained RVR. In patients who received 24 weeks of treatment, 88% attained SVR compared with 93% of patients who received 48 weeks of therapy [14].…”

Section: Discussionmentioning

confidence: 99%

Peginterferon alfa‐2b plus weight‐based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response

Craxı̀

Koutsounas

Ogurtsov

et al. 2011

Journal of Viral Hepatitis

View full text Add to dashboard Cite

SUMMARY. In chronic hepatitis C (CHC), treatment duration may be individualized according to time to first undetectable hepatitis C virus (HCV) RNA, with patients who attain undetectable HCV RNA early in treatment being candidates for shorter regimens. The aim of this study was to determine the relapse rate in patients with CHC genotype (G) 1 infection and low baseline viral load who achieved undetectable HCV RNA by week 4 [rapid virologic response (RVR)] when treated for 24 weeks. This was an open-label, multicentre, noninterventional study. Adult patients with G1 CHC infection and baseline viral load <600,000 IU/mL who attained RVR were treated with peginterferon alfa-2b (1.5 lg/kg/week) plus ribavirin (800-1200 mg/day) for 24 weeks, then followed for a further 24 weeks. The primary endpoint was relapse rate, defined as the proportion of patients with undetectable HCV RNA at treatment week 24 and detectable HCV RNA at week 24 follow-up. The secondary efficacy endpoint was sustained virologic response (SVR). Overall, 170 patients were included in the efficacy-evaluable population. The relapse rate was 9.7% (16/165, 95% confidence interval: 0.06-0.15), and SVR was attained by 149 of 170 patients (87.6%). Virologic outcomes were consistent regardless of age, gender, body weight and genotype. Seven patients reported treatment-emergent serious adverse events (AEs), and four patients discontinued treatment because of an AE. This study further demonstrates that peginterferon alfa-2b plus weight-based ribavirin for 24 weeks is an effective treatment strategy for treatment-naive patients with G1 CHC and low viral load who attain RVR.

show abstract

54 Completely Individualized Treatment Durations (24, 30, 36, 42, 48, 60 or 72 Weeks) With Peginterferon-Alfa-2b and Ribavirin in HCV Genotype 1-Infected Patients (Indiv-2 Study)

Cited by 7 publications

References 0 publications

The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C

The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C

IL28B single nucleotide polymorphisms in the treatment of hepatitis C

Peginterferon alfa‐2b plus weight‐based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response

Contact Info

Product

Resources

About